Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | NQO2 | P16083 | 4/20 | 0.41 |
| ▸ | NPC1 | O15118 | 3/20 | 0.41 |
| ▸ | RAB9A | P51151 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | G6PD | P11413 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.40 |
| ▸ | RELA | Q04206 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9310828 | 0.80 | GAA (0.66) | ALOX15ATMNQO2NPC1RAB9A | |
| SCHEMBL4512720 | 0.78 | HTT (0.63) | HTTALOX15NPC1RAB9ALMNA | |
| SCHEMBL13735279 | 0.78 | NQO2 (0.46) | ALOX15ATMNQO2NPC1RAB9A | |
| SCHEMBL13164798 | 0.77 | ALOX15 (0.43) | ALOX15ATMNQO2NPC1RAB9A | |
| SCHEMBL11685051 | 0.77 | CYP3A4 (0.68) | HTTALOX15ATMNPC1RAB9A | |
| SCHEMBL4510430 | 0.77 | HTT (0.61) | HTTALOX15NPC1RAB9ALMNA | |
| SCHEMBL17038145 | 0.73 | NPC1 (0.43) | HTTALOX15ATMNQO2NPC1 | |
| SCHEMBL18618286 | 0.73 | ALOX15 (0.66) | ALOX15ATMNPC1RAB9ALMNA | |
| SCHEMBL13826794 | 0.72 | TP53 (0.41) | ALOX15ATMNQO2NPC1RAB9A | |
| SCHEMBL11339029 | 0.71 | ALOX15 (0.47) | HTTALOX15ATMNQO2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3181555-B1 | BENZOTHIAZOLE COMPOUNDS AND THEIR PHARMACEUTICAL USE | GILEAD SCIENCES INC (US) | 2018-11-28 | — | — | EP | disclosed |
| US-9879023-B2 | Therapeutic compounds | GILEAD SCIENCES, INC. (US) | 2018-01-30 | — | — | US | disclosed |
| EP-3181555-A1 | BENZOTHIAZOLE COMPOUNDS AND THEIR PHARMACEUTICAL USE | Gilead Sciences, Inc. (US) | 2017-06-21 | — | — | EP | disclosed |
| US-20170088554-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2017-03-30 | — | — | US | disclosed |
| EP-2699558-B1 | BENZOTHIAZOLE COMPOUNDS AND THEIR PHARMACEUTICAL USE | GILEAD SCIENCES INC (US) | 2016-11-23 | — | — | EP | disclosed |
| US-9464096-B2 | Therapeutic compounds | GILEAD SCIENCES, INC. (US) | 2016-10-11 | — | — | US | disclosed |
| US-20160024104-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2016-01-28 | — | — | US | disclosed |
| US-9006229-B2 | Benzothiazole compounds and their pharmaceutical use | GILEAD SCIENCES, INC. (US) | 2015-04-14 | — | — | US | disclosed |
| EP-2699558-A1 | BENZOTHIAZOLE COMPOUNDS AND THEIR PHARMACEUTICAL USE | Gilead Sciences, Inc. (US) | 2014-02-26 | — | — | EP | disclosed |
| US-20140045818-A1 | BENZOTHIAZOLE COMPOUNDS AND THEIR PHARMACEUTICAL USE | GILEAD SCIENCES, INC. (US) | 2014-02-13 | — | — | US | disclosed |
| WO-2012145728-A1 | BENZOTHIAZOLE COMPOUNDS AND THEIR PHARMACEUTICAL USE | GILEAD SCIENCES, INC. (US) | 2012-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170088554-A1 | THERAPEUTIC COMPOUNDS | FURIN, NFATC1, NPC1 | HTT 1667/4885ALOX15 2002/4885ATM 2554/4885 |
| US-20140045818-A1 | BENZOTHIAZOLE COMPOUNDS AND THEIR PHARMACEUTICAL USE | FURIN, NFATC1, RUNX1 | HTT 1336/4885ALOX15 2300/4885ATM 1492/4885 |
| US-20160024104-A1 | THERAPEUTIC COMPOUNDS | NFATC1, FURIN, NPC1 | HTT 1733/4885ALOX15 2032/4885ATM 2630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.